Detailed Narrative
Daraxonrasib in Pancreatic Cancer
Revolution Medicines highlighted the transformational impact of daraxonrasib, with its New Drug Application accepted by the FDA following compelling Phase III RASolute 302 results. The EMA also recognized daraxonrasib as a high priority, initiating a phase review to accelerate assessment. The company is actively preparing for a successful launch, having established commercial infrastructure and an expanded access program to serve patients quickly and broadly.
Expanded Access Program (EAP) Success
The FDA-cleared Expanded Access Program for daraxonrasib has seen significant progress, activating sites in almost all 50 U.S. states and Puerto Rico. The company has approved over 90% of reviewed requests, providing daraxonrasib to more than 2,000 eligible patients. This rapid uptake underscores the high unmet need and interest in daraxonrasib for previously treated metastatic pancreatic cancer.
Pancreatic Cancer Pipeline Expansion
Beyond previously treated disease, Revolution Medicines is prosecuting a comprehensive development strategy in pancreatic cancer. Enrollment continues in Phase III RASolute 303 (first-line metastatic) and 304 (adjuvant) for daraxonrasib, and RASolute 305 (first-line metastatic) for zoldonrasib. The company also initiated RASolute 309, evaluating the novel doublet of daraxonrasib plus zoldonrasib in the first-line setting, reflecting a broad portfolio approach.
Zoldonrasib and Daraxonrasib Doublet Data in PDAC
New data presented at ESMO GI reinforced zoldonrasib's compelling profile. In first-line RAS G12D pancreatic cancer, zoldonrasib combined with FOLFIRINOX or gemcitabine plus nab-paclitaxel showed objective response rates of 82% and 61%, respectively. The daraxonrasib plus zoldonrasib doublet demonstrated preliminary clinical activity in second and third-line RAS G12D PDAC, with objective response rates of 50% and 47%, and median progression-free survival of 9.6 months and 7.6 months, respectively.
NSCLC Pipeline and Strategy
Non-small cell lung cancer represents another major opportunity, with RAS mutations present in approximately 30% of patients. Daraxonrasib received Breakthrough Therapy Designation for previously treated metastatic NSCLC with KRAS mutations other than G12C. The company's mutant-selective inhibitors (elironrasib, zoldonrasib, RMC-5127) have the potential to address over 70% of RAS-driven mutations in this disease, positioning Revolution Medicines uniquely to meet significant unmet needs.
Zoldonrasib and Elironrasib in First-Line NSCLC
Highly encouraging antitumor activity was observed for zoldonrasib and elironrasib in combination with pembrolizumab and chemotherapy in first-line NSCLC. Zoldonrasib achieved an 82% objective response rate and 100% disease control rate in KRAS G12D NSCLC. Elironrasib demonstrated an 85% objective response rate, 97% disease control rate, and 95% six-month progression-free survival rate in RAS G12C NSCLC, supporting their advancement into registrational development.
Financial Position and Investment Strategy
The company ended Q2 2026 with a strong cash and investments balance of $3.9 billion, including proceeds from recent public offerings and a royalty tranche. This financial strength supports an increased investment strategy, with full-year GAAP operating expenses now projected between $2.1 billion and $2.2 billion. This investment is driven by accelerated manufacturing, clinical development across multiple programs, and expanded commercial readiness efforts globally.